Update on GSK's response to the novel coronavirus (COVID-19): your questions answered

As the coronavirus (COVID-19) continues to affect communities in the U.S. and globally, our hearts go out to those impacted. We are closely monitoring the situation and updating our plans as the situation evolves. Our priorities are to safeguard the health and well-being of all of our employees, limit the spread of the disease, and continue to make our products available to the patients and consumers that need them.

As a global healthcare company, we'll continue to make decisions informed by science and in partnership with health authorities. That's why I want to share steps we're taking to protect your health and well-being and that of our employees, and our communities:

Ensuring medicine supply and access.

At this time, there is no impact on our ability to make our medicines, vaccines, and consumer healthcare products. We continue to closely monitor all parts of our supply chains and assess possible plans of action that may be needed in case the situation persists or worsens. We are experiencing an increase in demand for some of our respiratory products, and we are actively managing supply.

Contributing to the fight against COVID-19.

GSK is using our science, technology, and portfolio to support development of products for prevention/treatment of COVID-19. As the world's largest vaccines maker, we're also working with key partners to identify ways of preventing the virus.

GSK is donating $10 million to The COVID-19 Solidarity Response Fund, created by the UN Foundation and the World Health Organization (WHO). The fund will support the WHO and its partners in their efforts to prevent, detect, and manage the pandemic, particularly where the needs are the greatest.

To learn more about our actions to support the global response to COVID-19, visit our COVID-19 Resource Center.

Ready to help.

If you have a question or concern about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

If you have a question or concern about the impact of COVID-19 on your health, your prescription medicines, or your vaccines, please call your healthcare provider. They will have the appropriate information for your specific situation and needs.

If you're not sure if your prescription medication is a GSK product, you can search for it here.

Our mission is to support and keep our customers, healthcare workers, and employees safe during this time. The situation is rapidly changing and we will closely monitor it. Stay safe and healthy.

Sincerely,

Maya Martinez-Davis
President, U.S. Pharmaceuticals

Last updated: March 26, 2020

We're working with companies and research groups across the world on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.

We recently announced that GSK joined forces with Sanofi, bringing together two of the world's largest vaccines companies in collaboration to fight COVID-19. The two companies expect a candidate vaccine to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.

To learn more about our actions to support the global response to COVID-19, including vaccine development, visit our COVID-19 Resource Center.

Taking care of your health is the most important thing right now. This means continuing to take any medication as prescribed by your healthcare provider. If you have questions about your medications or your risk of COVID-19, please contact your healthcare provider.

If you have a question about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

Please talk to your healthcare provider before making any changes. Unless your healthcare provider recommends a change, you should continue to receive your GSK vaccinations as prescribed.

If you have questions around getting your next dose, please contact the GSK Response Center at 1-888-825-5249.

Right now, we're making our medicines, vaccines, and consumer healthcare products as usual. Rest assured that we're monitoring our supply chains closely and assessing possible plans of action that may be needed in case the situation persists or worsens. Some of our respiratory products are in greater demand, and we're actively managing those supplies.

If you have a question about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

GSK is sensitive to the needs of patients who struggle to afford healthcare services, including medicines and vaccines. GSK Patient Assistance programs for patients in the U.S., Puerto Rico, and U.S. Virgin Islands provide some medicines and vaccines at no cost to patients who meet program eligibility criteria.

To see if you're eligible, click the appropriate link below:

Oncology products BENLYSTA or NUCALA Other GSK prescription medicines

To find coupons and free trial offers for GSK medications, click the links below:

Free Trial Offers Dollars-Off Coupons

GSK is using our science, technology, and portfolio to support development of products for prevention/treatment of COVID-19. As the world's largest vaccines maker, we're also working with key partners to identify ways of preventing the virus.

Hear from our CEO, Emma Walmsley as she discusses GSK's response to COVID-19 including our collaboration with Sanofi to develop an adjuvanted COVID-19 vaccine, our commitment to access and investment in long-term pandemic preparedness.

GSK is also donating $10 million to The COVID-19 Solidarity Response Fund, created by the UN Foundation and WHO. The Fund will support the WHO and it's partners in their efforts to prevent, detect, and manage the pandemic, particularly where the needs are greatest.

GSK has also started new volunteering processes for people working at the company, to allow those with medical expertise to provide support to frontline health workers. In addition, our salesforce personnel have started to help with delivery of PPE and testing equipment, and our specialists, such as procurement leaders, are working with national governments on developing supply chains.

To learn more about our actions to support the global response to COVID-19, visit our COVID-19 Resource Center.

If you have a question about GSK products, vaccines, product availability, and/or need to report potential product side effects, please contact the GSK Response Center at 1-888-825-5249.

If you have a question or concern about the impact of COVID-19 on your health, your prescription medicines, or your vaccines, please contact your healthcare provider. They will have the appropriate information for your specific situation and needs.

If you're not sure if your prescription medication is a GSK product, you can search for it here.

Last updated: April 24, 2020

Please bookmark this page and check back for updates as new information becomes available.